(Total Views: 529)
Posted On: 01/13/2022 5:04:16 PM
Post# of 149074
A partner? Maybe… let’s put some logic behind it… what if I was a CEO of a mid size Pharmaceutical company. Let’s be completely clear about this I am not a CEO. Not that anyone was confused… What if… I heard by whatever means that the 350mg dose met primary and secondary end points and even though it was not a blinded trial still showed really great results. If this CEO knew we were waiting for the results of our double blinded 700mg dose and heard a scheduled webcast that could possibly have those results. Then made that call at the end of the day yesterday to make an partner offer that was conditional and that the results were not made public while a offer was made and negotiations started yesterday after hours. This would be the most crafty business savvy CEO now wouldn’t it?
Let’s speculate why a CEO who was looking to be first to offer and didn’t want a bidding war from a 1000 pharmaceutical companies to derail them from making the very first offer that would expire if the results were made public. This would be a shrewd business move to eliminate any competition and secure a deal of what could be the largest ever medical indication in the world to date. Nash applies to as much as 30% of the worlds population. This is not something you ignore and if you think you can make the first offer. This would be huge for any company big or small. Making a good enough offer is what would drive the thought of not having to waiting for the competition to make competing offers. A smart CEO would make the very best offer possible to seize the opportunity before others were involved. Let’s face it… Nash has been a unicorn for the whole pharmaceutical community and nobody has anything really close and many drugs have failed.
With conditions like every company searching and no luck so far. The unicorn of the medical fields in a treatment for NAFLD and even to reverse Nash would be astronomical in a market return. Let’s not under sell what we might have. Just this fact alone make all the effort of a really smart shrewd business CEO to be the first in-line… now… show me the money!
Let’s speculate why a CEO who was looking to be first to offer and didn’t want a bidding war from a 1000 pharmaceutical companies to derail them from making the very first offer that would expire if the results were made public. This would be a shrewd business move to eliminate any competition and secure a deal of what could be the largest ever medical indication in the world to date. Nash applies to as much as 30% of the worlds population. This is not something you ignore and if you think you can make the first offer. This would be huge for any company big or small. Making a good enough offer is what would drive the thought of not having to waiting for the competition to make competing offers. A smart CEO would make the very best offer possible to seize the opportunity before others were involved. Let’s face it… Nash has been a unicorn for the whole pharmaceutical community and nobody has anything really close and many drugs have failed.
With conditions like every company searching and no luck so far. The unicorn of the medical fields in a treatment for NAFLD and even to reverse Nash would be astronomical in a market return. Let’s not under sell what we might have. Just this fact alone make all the effort of a really smart shrewd business CEO to be the first in-line… now… show me the money!
(14)
(0)Scroll down for more posts ▼
